Trial · NCT01779882
Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
NCT01779882, Not applicable, Completed, University Hospital, Basel, Switzerland
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT. Trials, record NCT01779882. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01779882
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
- NCT number
- NCT01779882
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 72 participants, actual
- Lead sponsor
- University Hospital, Basel, Switzerland
- Conditions
- Myeloid Leukemia, Precursor Myeloid Neoplasms, Lymphoid Neoplasms
- Interventions
Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
- First posted
- 2013-01-30
- Last updated
- 2018-03-02
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Liver toxicity | Day 30 | Liver toxicity, assessed as absolute serum values of ASAT, ALAT, GGT, Alkaline Phosphatase, bilirubin at day 30. |
| Secondary | VOD | Day 30 | Incidence and severity of "veno occlusive disease (VOD)" at day 30 |
| Secondary | Acute graft-versus-host disease (GvHD) | Day 30 and Day 100 | Incidence and severity of acute GVHD, by organ (skin, liver, gut) at day 30 and day 100 |
| Secondary | Toxicity | Day 30 and Day 100 | Organ toxicity at day 30 and day 100 |
| Secondary | Efficacy | Day 30 and Day 100 | Survival, relapse and non-relapse mortality at day 30 and day 100 |
| Secondary | Cumulative liver values | Day 0, 10, 20 and 30 | Cumulative serum values of aspartate transaminase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyltransferase (GGT), Alkaline Phosphatase, bilirubin for days 0, 10, 20 and 30 |
| Secondary | Maximum liver values | Day 0, 10, 20 and 30 | Maximum serum values of ASAT, ALAT, GGT, alkaline phosphatase (AP), bilirubin at any time between day 0 and day 30 |
| Other | Cytokines measurement | Day -8, 0, 10, 20 and 30 | To test the correlation between order of application of the conditioning regimen and the levels of proinflammatory cytokines as well as the correlation between levels of cytokines and development of acute GVHD, plasma samples will be collected at different time points. |
| Other | Pharmacogenomics | Day -8, -3 and 0 | The current hypothesis is that some functional polymorphisms of genes, which control important enzymes in BU and CY metabolism, contribute to the observed interindividual variability in toxicity after allogeneic HSCT. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01779882
GET https://conductscience.org/api/trials/v1/NCT01779882/registered